{"schema_version":"secwatch.filing_event.v1","accession":"0000009326-25-000012","form_type":"8-K","ticker":"BCPC","cik":"0000009326","company_name":"BALCHEM CORP","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.733469+00:00","generated_at":"2026-05-17T22:41:37.527542+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Balchem Q2 2025: record net sales $255.5M, adj. EPS $1.27 beat","bullets":["Net sales $255.5M, +9.1% YoY; GAAP EPS $1.17 vs $0.98 prior year quarter.","Record adjusted EBITDA $69.2M (+11.2%); adjusted EPS $1.27 vs $1.09.","All three segments grew; record sales and earnings in Human Nutrition & Health and Specialty Products.","Plans new $36M micro-encapsulation facility in Orange County, NY, pending county approval.","EU imposes provisional anti-dumping duties of 95.4%-120.8% on Chinese choline chloride imports effective July 1, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000009326-25-000012","json":"https://secwatch.observer/filing/0000009326-25-000012.json","markdown":"https://secwatch.observer/filing/0000009326-25-000012.md","text":"https://secwatch.observer/filing/0000009326-25-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/9326/000000932625000012/0000009326-25-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/9326/000000932625000012/bcpc-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:41:37.527542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}